Analysis of the expression patterns and clinical relevance of m 6 A regulators in 33 cancer types.
Chundi GaoHaiyang YuHuayao LiCun LiuXiaoran MaJing ZhuangChanggang SunPublished in: Future oncology (London, England) (2021)
Background: The role of N6-methyladenine (m 6 A) RNA methylation in a variety of biological processes is gradually being revealed. Methods: Here, we systematically describe the correlation between the expression pattern of m 6 A RNA methylation regulatory factors and clinical phenotype, immunity, drug sensitivity, stem cells and prognosis in more than 10,000 samples of 33 types of cancer. Results: The results show that there are significant differences in the expression of 20 m 6 A RNA methylation regulatory factors in different cancers, and there was a significant correlation with the analysis indicators. Conclusion: In this study, the m 6 A RNA methylation regulatory factor was found not only to potentially assist in stratifying the prognosis but also to predict or improve the sensitivity of clinical drug therapy.
Keyphrases
- poor prognosis
- stem cells
- genome wide
- transcription factor
- dna methylation
- papillary thyroid
- binding protein
- nucleic acid
- squamous cell
- gene expression
- emergency department
- squamous cell carcinoma
- childhood cancer
- long non coding rna
- mesenchymal stem cells
- drug induced
- replacement therapy
- electronic health record
- data analysis
- smoking cessation